Bioresorbable Polymer Articles & Analysis
8 news found
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 ...
Clinical studies have shown that a DES prevents positive adaptive remodeling,5 inhibits vessel compliance and dilation in response to the body’s changing blood flow needs,6,7 and causes vessel straightening, which has been associated with increased MACE.8 The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating, having a radial strength similar to DES. Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike DES. ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike ...
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of its Liver and Pancreas ...
ByRegenity